Lisa-Marie Lanz

机构：German Cancer Research Center, Heidelberg University

发表论文 8 篇 · 总被引 35 次 · h-index 3

代表论文

• Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a N2M2 umbrella trial (2025 · Nature Medicine · 被引 13)
• INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas (2023 · Neurological Research and Practice · 被引 12)
• IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial (2026 · Nature Cancer · 被引 3)
• Author Correction: IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial (2026 · Nature Cancer · 被引 2)
• N2M2/NOA-20: Phase I/IIa umbrella trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. (2024 · Journal of Clinical Oncology · 被引 2)
• KS01.5.A LATE BREAKING ABSTRACT: LONG-TERM FOLLOW-UP OF PATIENTS WITH NEWLY DIAGNOSED IDH-MUTANT ASTROCYTOMA AFTER IDH1-VAC TREATMENT (2023 · Neuro-Oncology · 被引 2)